Things got off to an inauspicious start for the Mead boys team on Friday. Delayed a day to play their first postseason game ...

The door into the second encounter of Sundered Doctrine is a small test, set to teach you the mechanics you need to know. You ...

Tines CEO Eoin Hinchy discusses the company's latest $125M funding round, putting the company in unicorn territory with a ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.-based biotech firm to debut this ...

From muscle-bound castles to lavish manor houses, the world is filled with fine stately homes – and many of them happen to be ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million.

Rupeeflo raised $1 million in pre-seed funding to simplify banking and investing for NRIs. The platform offers seamless ...

Despite its population of five million, Guadalajara, Mexico’s second city, can feel like a village — one that's packed with ...

The concave “ski slope” lugs are the signature feature of the Maze III’s brand-new case. Farer The case is also an entirely different shape. It’s now a more traditional round shape with more detailed ...

IF a Greek Cypriot dancer ever says he’s lost his glasses, there’s a good chance they’ll be on his head. No, not his specs, ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...

At long last, you can live out your caftan-covered “White Lotus” fantasies. But please, I beg of you, do so safely and ...